These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38320519)

  • 1. Targeting Androgen Receptor Mutations in Metastatic Castration-Resistant Prostate Cancer with a Novel Androgen Biosynthesis Inhibitor.
    Gao X
    NEJM Evid; 2024 Jan; 3(1):EVIDe2300298. PubMed ID: 38320519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the androgen receptor signaling pathway in advanced prostate cancer.
    Chung C; Abboud K
    Am J Health Syst Pharm; 2022 Jul; 79(15):1224-1235. PubMed ID: 35390118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Systemic Treatment in Prostate Cancer Patients With Visceral Metastasis: A Systematic Review, Meta-analysis, and Network Meta-analysis.
    Yanagisawa T; Rajwa P; Kawada T; Mori K; Fukuokaya W; Petrov P; Quhal F; Laukhtina E; von Deimling M; Bianchi A; Majdoub M; Pradere B; Kramer G; Kimura T; Shariat SF
    J Urol; 2023 Sep; 210(3):416-429. PubMed ID: 37339479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptor signaling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration-sensitive prostate cancer.
    Mitsiades N; Kaochar S
    Endocr Relat Cancer; 2021 Jul; 28(8):T19-T38. PubMed ID: 34128827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to Hormonal Therapy in Prostate Cancer.
    Berruti A; Dalla Volta A
    Handb Exp Pharmacol; 2018; 249():181-194. PubMed ID: 28353036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the androgen receptor in metastatic castrate-resistant prostate cancer: A review.
    Anantharaman A; Friedlander TW
    Urol Oncol; 2016 Aug; 34(8):356-67. PubMed ID: 26706121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of androgen receptor alterations on cell-free DNA genomic profiling on survival outcomes in metastatic castration-resistant prostate cancer.
    Tripathi N; Thomas VM; Sayegh N; Gebrael G; Chigarira B; Jo Y; Li H; Sahu KK; Nussenzveig R; Nordblad B; Swami U; Agarwal N; Maughan BL
    Prostate; 2023 Dec; 83(16):1602-1609. PubMed ID: 37644774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer.
    Schalken J; Fitzpatrick JM
    BJU Int; 2016 Feb; 117(2):215-25. PubMed ID: 25818596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer.
    Sharp A; Welti J; Blagg J; de Bono JS
    Clin Cancer Res; 2016 Sep; 22(17):4280-2. PubMed ID: 27330057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
    Guo C; Yeh S; Niu Y; Li G; Zheng J; Li L; Chang C
    Cancer Lett; 2017 Jul; 397():133-143. PubMed ID: 28323036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen receptor mutations for precision medicine in prostate cancer.
    Shiota M; Akamatsu S; Tsukahara S; Nagakawa S; Matsumoto T; Eto M
    Endocr Relat Cancer; 2022 Oct; 29(10):R143-R155. PubMed ID: 35900853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
    Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
    Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Independent prognostic impact of plasma NCOA2 alterations in metastatic castration-resistant prostate cancer.
    Fettke H; Kwan EM; Bukczynska P; Steen JA; Docanto M; Ng N; Parente P; Mant A; Foroughi S; Pezaro C; Hauser C; Nguyen-Dumont T; Southey MC; Azad AA
    Prostate; 2021 Sep; 81(13):992-1001. PubMed ID: 34254334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer.
    Maughan BL; Antonarakis ES
    Curr Treat Options Oncol; 2015 Dec; 16(12):57. PubMed ID: 26537882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second generation androgen receptor antagonists and challenges in prostate cancer treatment.
    Chen Y; Zhou Q; Hankey W; Fang X; Yuan F
    Cell Death Dis; 2022 Jul; 13(7):632. PubMed ID: 35864113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer.
    Harris AE; Metzler VM; Lothion-Roy J; Varun D; Woodcock CL; Haigh DB; Endeley C; Haque M; Toss MS; Alsaleem M; Persson JL; Gudas LJ; Rakha E; Robinson BD; Khani F; Martin LM; Moyer JE; Brownlie J; Madhusudan S; Allegrucci C; James VH; Rutland CS; Fray RG; Ntekim A; de Brot S; Mongan NP; Jeyapalan JN
    Front Endocrinol (Lausanne); 2022; 13():1006101. PubMed ID: 36263323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. siRNA-based approaches for castration-resistant prostate cancer therapy targeting the androgen receptor signaling pathway.
    Yu Y; Papukashvili D; Ren R; Rcheulishvili N; Feng S; Bai W; Zhang H; Xi Y; Lu X; Xing N
    Future Oncol; 2023 Sep; 19(30):2055-2073. PubMed ID: 37823367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Inhibitors of the androgen receptor N‑terminal domain : Therapies targeting the Achilles' heel of various androgen receptor molecules in advanced prostate cancer].
    Hupe MC; Offermann A; Perabo F; Chandhasin C; Perner S; Merseburger AS; Cronauer MV
    Urologe A; 2018 Feb; 57(2):148-154. PubMed ID: 29147733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide.
    Rathkopf DE; Smith MR; Ryan CJ; Berry WR; Shore ND; Liu G; Higano CS; Alumkal JJ; Hauke R; Tutrone RF; Saleh M; Chow Maneval E; Thomas S; Ricci DS; Yu MK; de Boer CJ; Trinh A; Kheoh T; Bandekar R; Scher HI; Antonarakis ES
    Ann Oncol; 2017 Sep; 28(9):2264-2271. PubMed ID: 28633425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.